AP Sports SummaryBrief at 6:11 p.m. EST( MENAFN - GetNews) Schneider National, Inc., a leading transportation and logistics services company, has entered into a definitive agreement to acquire Cowan Systems, LLC, a dedicated contract carrier based in Baltimore, Md., and its affiliated entities. The transaction, announced today, is valued at approximately $390 million in cash, with additional agreements to purchase related Real estate assets for about $31 million. Cowan Systems brings to Schneider a dedicated fleet of approximately 1,800 trucks and 7,500 trailers, serving customers in the retail, consumer goods, food and beverage, industrial, and building materials sectors. This acquisition is set to enhance Schneider's Dedicated segment, which will now operate over 8,400 tractors, representing around 70% of its Truckload fleet. Mark Rourke, Schneider's President and CEO, emphasized that the purchase of Cowan Systems aligns with the company's strategic vision to focus on customer-centric Dedicated solutions. Cowan Systems, which was founded in 1924, will continue to operate as a wholly owned subsidiary of Schneider, maintaining its brand and workforce. The acquisition is projected to be accretive to Schneider's earnings per share within the first year, excluding anticipated synergies. The closing of the deal, expected in the fourth quarter of 2024, is subject to customary conditions and will be financed through existing cash and borrowings under Schneider's new $400 million credit facility. The integration of Cowan Systems follows Schneider's pattern of acquiring dedicated contract carriers, including Midwest Logistics Systems and M&M Transport Services, LLC. The financial results of Cowan Systems will be reported within Schneider's Truckload and Logistics business segments after the completion of the transaction. Legal advisory for Schneider was provided by Scopelitis, Garvin, Light, Hanson & Feary, while Stifel Financial Corp (NYSE:SF). and Scudder Law Firm advised Cowan Systems on financial and legal matters, respectively. This announcement is based on a press release statement and reflects the company's expectations and projections about the acquisition's future financial performance and operational integration. In other recent news, Schneider National has seen a flurry of activity from analyst firms following its recent third-quarter earnings report. The company reported steady revenues of $1.2 billion, with adjusted diluted earnings per share falling slightly from $0.20 to $0.18. Benchmark, BofA Securities, and Evercore ISI have all adjusted their outlooks on the transportation and logistics services company. Benchmark raised its stock price target for Schneider National to $32.00, maintaining a Buy rating. This followed a third-quarter earnings report that fell short of expectations, with adjusted operating income reported at $44.3 million. Despite challenges, Schneider National's Dedicated and Intermodal business segments showed resilience and improvement, respectively. BofA Securities upgraded Schneider National's rating from Underperform to Buy, raising the price target to $34.00. This positive outlook follows the recent U.S. election and anticipates benefits to the truckload industry. However, due to weaker than expected performance in the third quarter, BofA Securities reduced its earnings per share estimates for 2024 and 2025. Evercore ISI reduced Schneider National's price target from $27.00 to $26.00 while retaining an In Line rating. This follows Schneider National's third-quarter earnings report, which disclosed an adjusted earnings per share of $0.18, falling short of projections. The company's earnings were adversely affected by a weaker performance in the Truckload and Logistics segments. These are recent developments that provide insight into the current state of Schneider National. The company continues its commitment to shareholder returns, strategic growth, and operational efficiency, as evidenced by its ongoing share repurchase program. MENAFN30112024003238003268ID1108941449 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.Mbappe on target as Real beat Leganes 3-0
Hunter Syndrome Therapeutics Market Size in the 7MM is expected to grow by 2034, estimated DelveInsight 12-17-2024 07:42 PM CET | Health & Medicine Press release from: ABNewswire DelveInsight's "Hunter Syndrome Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth analysis of Hunter Syndrome epidemiology, market, and clinical development in Hunter Syndrome. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the hunter syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Discover Key Insights into the Hunter Syndrome Market with DelveInsight's In-Depth Report @ Hunter Syndrome Market Size [ https://www.delveinsight.com/sample-request/hunter-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Key Takeaways from the Hunter Syndrome Market Report * The total number of Hunter Syndrome Diagnosed Prevalent Cases in the 7MM was nearly 1,200 cases in 2023 and is projected to increase during the forecasted period. * The total number of Hunter Syndrome Diagnosed Prevalent Cases in EU4 and the UK for hunter syndrome was estimated to be nearly 350 cases in 2023. Germany had the highest prevalent cases followed by the UK. * MPS II typically affects only males, with symptoms becoming apparent at approximately 2-4 years of age. * It is estimated that about two-third of MPS II patients develop cognitive impairment with onset of symptoms between 1 to 3 years of age in the neuronopathic form. * Patients with MPS II are often classified as severe MPS II or mild MPS II. Severe form accounts for 65-70% of the cases. However, it slightly varies from country to country. * The leading Hunter Syndrome Companies such as Homology Medicine, Denali Therapeutics, Regenxbio, Takeda, JCR Pharmaceuticals, GC Pharma, Regenxbio, Sangamo Therapeutics, ArmaGen , and others * Promising Hunter Syndrome Therapies such as HMI-203, DNL310, RGX-121, SHP-609/ TAK-60 , and others Stay ahead in the Hunter Syndrome Therapeutics Market with DelveInsight's Strategic Report @ Hunter Syndrome Market Outlook [ https://www.delveinsight.com/sample-request/hunter-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Hunter Syndrome Epidemiology * Total Hunter Syndrome Diagnosed Prevalent Cases * Hunter Syndrome Severity-specific Cases Download the report to understand which factors are driving Hunter Syndrome Epidemiology trends @ Hunter Syndrome Prevalence [ https://www.delveinsight.com/sample-request/hunter-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Hunter Syndrome Marketed Drugs * ELAPRASE (idursulfase): Takeda Pharmaceuticals ELAPRASE is the first enzyme replacement therapy to be approved for people suffering from Hunter syndrome and it was launched in the US in July 2006 and in 2007 in the EU and Japan. ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older. The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age. * IZCARGO: JCR Pharmaceuticals IZCARGO is the world's first biological drug applied with the brain drug delivery technology J-Brain Cargo., which utilizes the transferrin receptor-mediated Fe/transferrin transport to the brain and was launched in Japan to treat patients with all forms of MPS II. In March 2021, JCR received approval in Japan for IZCARGO (10 mL, intravenous drip infusion), the first enzyme replacement therapy capable of crossing the blood-brain barrier. Sales of IZCARGO increased more than 10% year-on-year and progressing well. The revenue reached from JPY 1,070 million in Q1 2022 to JPY 1,372 in Q1 2024. Hunter Syndrome Emerging Drugs * Tividenofusp alfa (DNL310): Denali Therapeutics Tividenofusp alfa (DNL310) is a fusion protein composed of IDS fused to Denali's proprietary Enzyme Transport Vehicle (ETV), which is engineered to cross the BBB via receptor-mediated transcytosis into the brain and to enable broad delivery of IDS into cells and tissues throughout the body with the goal of addressing the behavioral, cognitive, and physical manifestations of MPS II. In March 2021, the US Food and Drug Administration granted Fast Track Designation to DNL310 for the treatment of patients with MPS II. In May 2022, the European Medicines Agency granted DNL310 Priority Medicines designation. * RGX-121: Regenxbio RGX121 is an investigational adeno-associated Virus (AAV) therapeutic for the treatment of MPS II. RGX121 is designed to use the NAV AAV9 vector to deliver the human IDS gene to cells in the Central Nervous System (CNS). RGX-121 is the only product in late-stage development with the potential to address neurocognitive development in patients diagnosed under the age of 2 years. In May 2023, RGX-121 received Regenerative Medicine Advanced Therapy (RMAT) designation. Moreover, the drug has also received Orphan Drug Designation (ODD, 2015), Rare Pediatric Drug Designation (RPDD, 2016), and Fast Track Drug Designation (FTD, 2018) from the US FDA. In October 2017, the EMA granted ODD to REGENXBIO for recombinant adeno-associated viral vector serotype 9 containing the human IDS gene. To know more about Hunter Syndrome treatment guidelines, visit @ Hunter Syndrome Treatment Market Landscape [ https://www.delveinsight.com/sample-request/hunter-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Hunter Syndrome Market Outlook The Hunter Syndrome Market is mainly dominated by ERT, along with a few major emerging products in the pipeline that are also based on the same principle of iduronate 2-sulfatase (I2S) ERT. The only approved therapy with idursulfase is ELAPRASE. However, one of the major drawbacks of ELAPRASE is its inability to cross the blood-brain barrier (BBB), which affects the product's efficacy. Hunter Syndrome Treatment Market The current Hunter syndrome treatment involves patients receiving infusion of the IDS enzyme, usually once a week. These infusions can help break down the accumulated glycosaminoglycans and can help alleviate symptoms and slow disease progression. However, the enzyme does not cross the blood-brain barrier, so the treatment does not help with cognitive or developmental symptoms. Learn more about the FDA-approved drugs for Hunter Syndrome @ Drugs for Hunter Syndrome Treatment [ https://www.delveinsight.com/sample-request/hunter-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Scope of the Hunter Syndrome Market Report * Coverage- 7MM * Study Period- 2020-2034 * Hunter Syndrome Companies- Homology Medicine, Denali Therapeutics, Regenxbio, Takeda, JCR Pharmaceuticals, GC Pharma, Regenxbio, Sangamo Therapeutics, ArmaGen, and others * Hunter Syndrome Therapies- HMI-203, DNL310, RGX-121, SHP-609/ TAK-60, and others * Hunter Syndrome Market Dynamics: Hunter Syndrome Market Drivers and Barriers * Hunter Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives Table of Content 1. Key Insights 2. Hunter Syndrome Market Overview at a Glance 3. Hunter Syndrome Market Disease Background and Overview: Hunter Syndrome 4. Diagnostic Algorithm for Hunter Syndrome 5. Hunter Syndrome Epidemiology and Patient Population 6. Country-Wise Epidemiology of Hunter Syndrome 7. Hunter Syndrome Treatment 8. Recognized Establishments 9. Hunter Syndrome Unmet Needs 10. Hunter Syndrome Marketed Profile 11. Hunter Syndrome: 7 Major Market Analysis 12. Hunter Syndrome KOL Reviews 13. Case Reports 14. Hunter Syndrome Market Drivers 15. Hunter Syndrome Market Barriers 16. SWOT Analysis 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=hunter-syndrome-therapeutics-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimated-delveinsight ] Phone: 9650213330 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage This release was published on openPR.IT exports rise by 33pc to $1.53bn in July-Nov
The Latest: Matt Gaetz withdraws his name from consideration as Trump’s attorney generalLouisiana Tech 85, S. Illinois 79, OTIf Benjamin Netanyahu stepped foot in Canada, he would be arrested, Prime Minister Justin Trudeau confirmed on Thursday after the International Criminal Court (ICC) Also included in the warrant are Netanyahu’s former Defense Minister Yoav Gallant, and a Hamas leader. Trudeau was in Newmarket on Thursday to make a when a reporter reminded him that under the warrants, Canadian law enforcement would be obligated to arrest Netanyahu if he entered the country. When asked if he would allow the arrest to happen, he replied: “As Canada has always said, it’s really important that everyone abide by international law, this is something we have been calling on since the beginning of the conflict,” a grim-looking Trudeau replied. “We are one of the founding members of the International Criminal Court (ICC),” he added. “We stand up for international law and we will abide by all the regulations and rulings of the international courts. This is just who we are as Canadians.” The announcement quickly drew both praise and condemnation. “We are ashamed that Canada would align itself with such a politicized decision,” the Centre for Israel and Jewish Affairs wrote in a social media post. “By doing so, Canada undermines international law, strains its alliance with the U.S., and harms its relationship with Israel. This decision erodes Canada’s role as a principled advocate for fairness and justice on the global stage.” The National Council of Canadian Muslims (NCCM) applauded Trudeau’s backing of ICC — the world’s top war-crimes court. “Today, the Prime Minister took a step in this direction by accepting that Canada would recognize these ICC arrest warrants. This means that Netanyahu and Gallant would be arrested if they stepped foot in Canada. This is an important moment. Canada has chosen to do the right thing.” The warrants against Netanyahu and Gallant allege Israel has used food as a weapon in its campaign against Hamas in Gaza. Israeli officials deny that charge. The court also issued an arrest warrant for Mohammed Deif — the head of Hamas’ armed wing for his role in the Oct. 7, 2023 attacks. Netanyahu, meanwhile, was quick to condemn the arrest warrant against him, saying Israel “rejects with disgust the absurd and false actions” by the court. In a statement released by his office, he said: “There is nothing more just than the war that Israel has been waging in Gaza.”
The expanded Big Ten is poised to be a major player in this season's College Football Playoff. The 18-team conference had three of the top-four teams in the AP poll this week — No. 1 Oregon, No. 2 Ohio State and No. 4 Penn State. A one-loss Indiana team is ranked 10th but is still very much a contender to make the playoff, given how many Southeastern Conference teams have three defeats or more. Indiana's rise has been perhaps the Big Ten's biggest story this season. Much of the spotlight was on newcomers Oregon, Southern California, UCLA and Washington, but aside from the top-ranked Ducks, that foursome has struggled to impress. Meanwhile, the Hoosiers won their first 10 games under new coach Curt Cignetti before losing at Ohio State last weekend. Oregon beat Ohio State 32-31 back in October, and if the Buckeyes beat rival Michigan this weekend, they'll earn a rematch with the Ducks for the Big Ten title. People are also reading... And it's entirely possible another matchup between those two teams awaits in the CFP. Star power Dillon Gabriel has quarterbacked Oregon to an unbeaten record, throwing for 3,066 yards and 22 touchdowns in 11 games. But don't overlook Iowa's Kaleb Johnson and his 21 rushing TDs, and quarterback Kurtis Rourke has been a big part of Indiana's improvement. Penn State's Abdul Carter has eight sacks and two forced fumbles and could be one of the top edge rushers drafted this year. Going bowling Oregon (11-0, 8-0), Ohio State (10-1, 7-1), Penn State (10-1, 7-1), Indiana (10-1, 7-1), Illinois (8-3, 5-3), Iowa (7-4, 5-3), Michigan (6-5, 4-4), Minnesota (6-5, 4-4), Washington (6-5, 4-4), Southern California (6-5, 4-5), Nebraska (6-5, 3-5) and Rutgers (6-5, 3-5) have already reached the six-win mark for bowl eligibility. Michigan State (5-6, 3-5) and Wisconsin (5-6, 3-5) can join them. Hot seats There may not be many firings in general at the top level of college football. The prospect of sharing revenue with athletes in the future might lead schools to be more judicious about shedding one coach and hiring a new one. Who should be most worried in the Big Ten? Well, Lincoln Riley is struggling to stay above .500 in his third season at USC. Purdue is 1-10, but coach Ryan Walters is only in his second season. Maryland's Mike Locksley has been there six years and his Terrapins are 4-7, but this was his first real step backward after guiding the team to three straight bowl wins. Cignetti has shown it is possible for a coaching change to push a previously moribund program to some impressive heights in a short amount of time — but the improvement has been more incremental at Michigan State following Jonathan Smith's arrival. Sherrone Moore wasn't a completely unknown commodity at Michigan after he won some massive games in place of a suspended Jim Harbaugh last year. But in his first season completely at the helm, the Wolverines have declined significantly following their national title a season ago. Youth movement The Big Ten is home to one of the most dynamic freshmen in the country in Ohio State receiver Jeremiah Smith. He has 52 catches for 899 yards and nine touchdowns. Highly touted quarterback Dylan Raiola has teamed up with fellow freshman Jacory Barney (49 catches) to lead Nebraska to bowl eligibility. Recruiting watch Ohio State is on track to land the Big Ten's top class, according to 247 Sports, but the big news recently was quarterback Bryce Underwood flipping from LSU to Michigan. If the Wolverines do in fact keep Underwood in his home state, that would be a big development for Moore. Be the first to know Get local news delivered to your inbox!Brokerages Set Kimbell Royalty Partners, LP (NYSE:KRP) Target Price at $20.50NEW YORK, Nov. 30, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation EW and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation . Investors have until December 13, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Edwards Lifesciences securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Patel v. Edwards Lifesciences Corporation , et al. , No. 24-cv-02221. What is the Lawsuit About? The Complaint alleges that Edwards is an international company that researches, develops, and provides products and technologies for heart valve repair and replacement therapies, as well as critical care monitoring solutions. Edwards categorizes its therapies and technologies into four categories: Transcatheter Aortic Valve Replacement ("TAVR"), Transcatheter Mitral and Tricuspid Therapies ("TMTT"), Surgical Structural Heart therapies, and Critical Care therapies. As alleged, Edwards consistently touted the TAVR platform, the significant unmet demand for TAVR, and the Company's ability to capitalize on that demand by scaling its various patient activation activities. These statements were allegedly materially false and misleading. In truth, TAVR's demand and growth had stalled as Defendants' patient activation activities failed to reach the perceived low-treatment-rate population and healthcare organizations prioritized other treatments over TAVR. On July 24, 2024, Edwards slashed guidance for TAVR for fiscal 2024 and announced disappointing financial results for TAVR for fiscal 2Q 24. This is allegedly because developments in new procedures, including Defendant's own TMTT, put significant strain on hospital structural heart teams such that they were underutilizing TAVR, despite the Company's continued claims of a significantly undertreated patient population. The news disclosed on July 24, 2024 caused a significant 31% decline in the price of Edwards stock, from $86.95 per share on July 24, 2024 to $59.70 per share on July 25, 2024. Click here if you suffered losses: https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation . What Can You Do? If you invested in Edwards Lifesciences you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation Or contact: Ross Shikowitz ross@bfalaw.com 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit https://www.bfalaw.com . https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation Attorney advertising. Past results do not guarantee future outcomes. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
CMS Energy Corp. stock rises Monday, still underperforms market‘Political Punchlines’: A Namibian election comedy show
AP Sports SummaryBrief at 5:21 p.m. ESTNone
Stockhead Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Painchek is awaiting US approval for its digital pain-assessment tool The US aged-care market is ten times bigger than Australia’s The company is also eyeing the much bigger infant market PainChek (ASX:PCK) CEO Philip Daffas has a simple vision for the company’s digital pain-assessment tool: “to be the next Australian technology that goes global”. To misquote Mandy Rice-Davies: he would say that, wouldn’t he? But as a former senior executive at Cochlear (ASX:COH) , Daffas knows a thing or two about what it takes to build a global device business. “You can’t buy true global business development experience. You certainly can’t learn it from a manual,” he says. There’s an encouraging precedent, in that Nanosonics (ASX:NAN) CEO Michael Kavanagh took over Daffas’s role as Cochlear’s head of marketing. Nanosonics went on to commercialise its medical probe sterilisation units which are now sold globally. Painchek doesn’t quite have the global reach of Nanosonics, but to date the company has won a meaningful presence in the local and UK markets for its eponymous mobile digital tool for aged-care facilities. Daffas started Painchek after being approached by a board member at Perth University, Mike Quinn who pointed out a novel pain-assessment technology being developed within the uni’s walls. Daffas become CEO in October 2016, when the company was known as Epat. “We were initially a research company, so we have gone from research to international commercialisation in eight years,” he says. Ditching the pen and paper Replacing pen-and-paper methods in favour of more objective AI, Painchek measures and records pain in aged-care and home care residents – typically suffering from dementia – and unable to verbalise their discomfort. It’s the world’s first regulatory-cleared medical device to assess pain for this cohort. Via a mobile camera, the Painchek app devises a 42-point profile covering nine microfacial features, body movement and behaviour. Since its first commercial sale in 2017, Painchek has won a circa 30% of the Australian aged care market – around 60,000 out of 200,000 beds – and an 8% share of the UK sector (around 40,000 out of 500,000 beds). Painchek has also started a live hospital trial at Scotland’s Royal Edinburgh Hospital. To date, Painchek has undertaken more than eight million assessments and has accrued the world’s biggest pain-management database. “Painchek is not just about providing a pain score, but also a pain profile,” Daffas says. “Two people with moderate to severe pain shouldn’t be treated the same, because their profile can be quite different. Some will require more care and some may need different medication.” Awaiting an FDA response Daffas is putting his Cochlear learnings to good use as the company tackles three further expansion paths: the US aged-care industry, the pre-verbal kids’ sector and the home-use market. The US aged-care market with its two million aged care beds – ten times the size of the Australian market. The company has lodged a US Food & Drug Authority (FDA) clearance submission, under the De Novo (new device) route. Having met with the agency to hone its approach, the company expects a positive response within the stipulated 150-day period. The US aged-care market is similarly structured to Australia’s, in that it is highly fragmented but with a handful of larger operators. In the US, one of them accounts for 50,000 beds. Painchek’s biggest Australia client to date, Bolton Clarke, accounts for 7,500 beds across multiple facilities. “We will build our own core sales team,” Daffas says. “From our ANZ and UK experience we know we need ground staff to build the business model.” Painchek also has an integration agreement with Point Click Care, a one-stop-shop care management platform that accounts for one million aged-care beds in the US and Canada. If FDA-cleared, the device should enable approval of the home care and infant devices under the easier ‘predicate’ route. Infant market is no child’s play The infant market is an even more glittering prize, given 1% of that market equates to the entire aged-care opportunity. Around 150 million kids are born annually and they won’t talk until they are around 12-18 months old (thereafter, they won’t shut up). “The Painchek infant app is built and at an early stage, with 50-100 families putting it through its paces to assess, treat, diarise and document the treatment,” Daffas says. This month the WA government agreed to fund development of an additional Painchek app for children living with disabilities. The support is by way of a $392,820 grant from the WA government’s Future Health Research and Innovation Fund. Moving to cash flow break-even As of the end of September Painchek had 100,322 contracted licences across 1600 aged-care facilities, with 61,705 implemented. By the end of November this number had grown sharply to 68,136, which the company attributes to changes including more defined rollout schedules with milestone payments. Last year Painchek reported revenue of $2.66 million, up 37% but the loss deepened to $8.3 million from $7.54 million previously (mostly due to one-off FDA clinical trial costs). The company says the current licences equate to $5 million of annual recurring revenue – enough to get it to operational breakeven within the ANZ and UK markets excluding research and development and corporate expenses. Meanwhile, the company has just raised $5.1 million in an underwritten Canaccord rights issue, at 2.5 cents per share (with attached options). Innovating in a tech-light sector Daffas says a successful device needs to be unique and prove it is solving a medical problem, such as reducing hospitalisations or medication costs. He says Painchek gained traction because it addressed the aged-care sector needs and now it intends to do the same in the larger home care and hospital markets (with initial sales in both sectors). He believes Painchek has gained traction because unlike in hospitals, the aged-care sector has been slow to adopt novel technology. “Tech starts in hospitals and moves to home and aged care, but Painchek has done the opposite.” Painchek’s momentum hasn’t translated to a valuation uplift, with its shares declining 32% year to date and 85% over the last five years. FDA approval in just a few months’ time could well be the catalyst that salves the shareholders’ pain. Originally published as Biocurious: Painchek’s aged care and infant market expansion plans could be much-needed salve More related stories Stockhead Mali gold miners see support Is the worst over for Mali gold miners? Bets today on ASX gold names suggest some investors may think so. Read more Stockhead ASX slips as Fed looms The ASX closed just into the red on Wednesday, ahead of another important Fed decision. Read more
NASHVILLE, Tenn.--(BUSINESS WIRE)--Dec 17, 2024-- Celero Commerce (“Celero”), a leading integrated electronic commerce solutions provider, today announced a new collaboration with EverBank, N.A., a national specialty bank serving clients across the United States, to enhance payment processing options for EverBank’s clients. Through this collaboration, EverBank will leverage Celero’s advanced payment and analytics platform to streamline financial operations for small business to larger commercial corporate clients, with a focus on expanding payment acceptance capabilities. The integration will enable a more flexible, seamless and scalable approach to payments, reinforcing EverBank’s dedication to providing innovative financial solutions to deliver the financial advantage clients deserve. “We founded Celero to deliver a proprietary suite of FinTech solutions tailored for financial institutions and small to mid-sized businesses,” said Celero founder and Chief Executive Officer Kevin Jones. “Paired with the superior service we offer, we know we can help deliver a better payments experience to EverBank’s customers.” Celero’s platform offers a comprehensive suite of services tailored to meet complex client requirements, including real-time payment capabilities, robust fraud prevention tools and in-depth financial analytics, all strategically aligned to streamline payment operations. “We are always looking for ways to make our clients’ lives easier and improve their experience of working with us, and Celero shares our mission of providing best-in-class payments solutions to give our clients an advantage,” said Lindsay Lawrence, Executive Vice President and Chief Operating Officer of EverBank. “By collaborating with Celero, we are offering a solution that adapts to our clients’ evolving needs, ensuring we continue to support their success and growth effectively.” About Celero Commerce Headquartered in Nashville, Celero Commerce is a full-service, integrated electronic commerce solutions provider powered by leading-edge technology, strategic partnerships, and business intelligence. Celero offers small and medium-sized businesses payment processing services, business management software, and data intelligence, empowering them to drive growth and profitability. Celero is a top ten non-bank processor of electronic payment transactions in the world. Visit https://www.celerocommerce.com/ to learn more. About EverBank EverBank, N.A. (“EverBank”) is a nationwide specialty bank providing high-value products and services to consumer and commercial clients nationwide. As a pioneer in online banking, we offer convenient digital access for clients 24/7, in addition to phone banking services and a network of financial centers across Florida and California. EverBank’s commitment is to deliver to their clients high-performing, high-yield solutions backed by exceptional service, always giving them the advantage they expect to make the most of their money. Visit everbank.com or connect and interact with us on Facebook, Instagram, LinkedIn, or X (formerly Twitter). EverBank is a Member FDIC. View source version on businesswire.com : https://www.businesswire.com/news/home/20241217424040/en/ CONTACT: Media Scott Farace scottf@celerocommerce.com (972) 533-5655 Media Michael Cosgrove Michael.Cosgrove@EverBank.com (904) 612-4160 KEYWORD: TENNESSEE UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: TECHNOLOGY PAYMENTS FINANCE FINTECH BANKING ELECTRONIC COMMERCE PROFESSIONAL SERVICES SOFTWARE DATA ANALYTICS DATA MANAGEMENT SOURCE: Celero Commerce Copyright Business Wire 2024. PUB: 12/17/2024 02:00 PM/DISC: 12/17/2024 02:00 PM http://www.businesswire.com/news/home/20241217424040/en